Nicholas Investment Partners LP Sells 16,110 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Nicholas Investment Partners LP lessened its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 9.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 157,635 shares of the company’s stock after selling 16,110 shares during the period. Nicholas Investment Partners LP owned approximately 0.32% of Enliven Therapeutics worth $3,547,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Millennium Management LLC grew its position in shares of Enliven Therapeutics by 108.6% during the 4th quarter. Millennium Management LLC now owns 50,804 shares of the company’s stock valued at $1,143,000 after acquiring an additional 26,449 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Enliven Therapeutics by 3.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company’s stock valued at $451,000 after acquiring an additional 718 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Enliven Therapeutics by 27.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock worth $30,001,000 after purchasing an additional 290,153 shares in the last quarter. Graham Capital Management L.P. boosted its position in Enliven Therapeutics by 67.3% during the fourth quarter. Graham Capital Management L.P. now owns 15,178 shares of the company’s stock valued at $342,000 after buying an additional 6,106 shares during the period. Finally, Deutsche Bank AG raised its stake in shares of Enliven Therapeutics by 51.7% during the fourth quarter. Deutsche Bank AG now owns 30,516 shares of the company’s stock valued at $687,000 after acquiring an additional 10,397 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

Insider Activity

In other news, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction on Friday, March 7th. The shares were sold at an average price of $21.44, for a total value of $142,940.48. Following the transaction, the chief operating officer now directly owns 323,310 shares of the company’s stock, valued at $6,931,766.40. The trade was a 2.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00. Following the transaction, the chief executive officer now directly owns 990,392 shares in the company, valued at approximately $20,629,865.36. This trade represents a 1.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 76,111 shares of company stock valued at $1,493,145 in the last quarter. 29.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, March 21st.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $20.03 on Wednesday. The business has a 50 day simple moving average of $18.99 and a 200-day simple moving average of $21.91. The firm has a market capitalization of $982.79 million, a price-to-earnings ratio of -10.54 and a beta of 1.07. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million for the quarter. As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.